Velasquez v. Centrome, Inc.

233 Cal. App. 4th 1191, 183 Cal. Rptr. 3d 150, 80 Cal. Comp. Cases 134, 2015 Cal. App. LEXIS 90
CourtCalifornia Court of Appeal
DecidedJanuary 30, 2015
DocketB247080
StatusPublished
Cited by31 cases

This text of 233 Cal. App. 4th 1191 (Velasquez v. Centrome, Inc.) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Velasquez v. Centrome, Inc., 233 Cal. App. 4th 1191, 183 Cal. Rptr. 3d 150, 80 Cal. Comp. Cases 134, 2015 Cal. App. LEXIS 90 (Cal. Ct. App. 2015).

Opinion

Opinion

BIGELOW, P. J.

— Plaintiff and appellant Wilfredo Velasquez appeals from a judgment after jury trial of his product-related personal injury action. Velasquez alleged his lung disease was caused by workplace exposure to a chemical compound, diacetyl, that was distributed by defendant and respondent Centróme, Inc., doing business as Advanced Biotech (Advanced). The trial court entered judgment on the jury’s special verdict, which included findings, as to multiple causes of action, that Advanced’s acts were not a substantial factor in causing harm to Velasquez.

*1194 After finding the issue relevant to Velasquez’s ability to receive a lung transplant, the trial judge advised the prospective jurors during jury selection that Velasquez is an undocumented immigrant. Velasquez claims the jurors who decided his case were incapable of being fair given their knowledge of his immigration status. We find the trial court erred when it disclosed Velasquez’s undocumented immigrant status to the venire of prospective jurors, and in denying a motion for mistrial. We find the denial of Velasquez’s motion for mistrial requires that the judgment be reversed.

FACTS

Background

In the summer of 2003, Velasquez started working as a temporary employee at Gold Coast, a company that made food flavorings. At some point in 2004, he became a permanent employee. While working at Gold Coast, Velasquez moved diacetyl, in both closed and open bags and containers, throughout the company’s facility. He breathed ambient diacetyl particles in the air while using a sprayer to mix diacetyl into batches of liquid and dry flavorings, and while hand pouring the compound into mixes. 1

During the time that Velasquez worked at Gold Coast, Advanced supplied roughly 80 percent of the diacetyl that Gold Coast used in its facility. Advanced did not manufacture the diacetyl. Advanced purchased the compound from suppliers then distributed it to customers like Gold Coast. Advanced attached material safety data sheets (MSDS’s) to the containers of diacetyl it distributed to its customers. The MSDS’s warned that diacetyl was “harmful by inhalation,” but did not include specific warnings about the risks of any particular diseases from exposure to the compound. At trial, it was undisputed that Advanced’s warnings were consistent with flavorings industry practices at the time that Velasquez was working at Gold Coast. The California Division of Occupational Safety and Health did not issue exposure limits for diacetyl until 2010, more than four years after Velasquez stopped working at Gold Coast. There were no federal regulations governing exposure limits for diacetyl while Velasquez worked at Gold Coast. Even by the time of trial of Velasquez’s current case in 2012, the Federal Drug Administration continued to classify diacetyl as “Generally Regarded as Safe.”

During a mixing incident in September 2005, Velasquez inhaled fumes from a concentration of compounds that included acetaldehyde, but not diacetyl. Following the incident, Velasquez experienced trouble breathing, and first sought medical attention for breathing issues. A doctor at a local *1195 hospital gave Velasquez an inhalator, along with a paper indicating he had a respiratory infection. When his breathing difficulties did not improve, Velasquez returned to the hospital two more times in the next two months. In November 2005, Velasquez’s supervisor took him to the “company clinic” at Gold Coast’s facility, where a “company doctor” told him he could not continue working for the company in his condition. Velasquez’s last day of employment at Gold Coast was November 16, 2005.

In late November 2005, Velasquez went to Mike Mirahmadi, M.D., for treatment. Velasquez complained of shortness of breath. Dr. Mirahmadi noted Velasquez was using an inhaler intended for asthma, and that Velasquez attributed his breathing problems to work. Dr. Mirahmadi instructed Velasquez to continue using the inhaler and to stop working for 30 days to see if absence from his workplace helped his symptoms. Dr. Mirahmadi referred Velasquez to a lung specialist. It is not clear from the parties’ briefs or the record on appeal whether Velasquez followed through on this medical plan. From January to August 2006, Randall Caldron, M.D., treated Velasquez. Dr. Caldron diagnosed Velasquez as suffering from a reactive airway disease or allergic rhinitis. Dr. Caldron prescribed medications commonly used for treating those conditions. According to his complaint, Velasquez was first diagnosed with bronchiolitis obliterans, a rare form of lung disease which is usually progressive and fatal, in December 2006. The circumstances of this first diagnosis are not readily apparent from the parties’ briefs on appeal, or their references to the record. 2

The Lawsuit and Trial

In April 2007, Velasquez filed a complaint for personal injuries against several manufacturers and distributors of chemical compounds used to make food flavorings, including Advanced. In June 2011, Velasquez filed his operative first amended complaint. Velasquez’s first amended complaint alleged various chemicals and chemical compounds to which he was exposed while working at Gold Coast caused his lung disease. The following causes of action, listed respectively, were eventually tried to a jury and submitted for its consideration by way of a special verdict form; negligence (breach of duty, including duty to warn of risks); negligence per se (negligence based on violations of regulations governing mandatory hazardous materials warnings); strict products liability — design defect (the consumer expectation test); strict products liability — design defect (the risk-benefit test); and strict products liability — failure to warn of risk that is unknown to user.

*1196 1. The Motions in Limine

In the months leading up to trial, Velasquez filed a number of motions in limine, including motion in limine No. 46 to preclude Advanced (and, at the time, a number of other defendants) from presenting any evidence or making any comment about his citizenship or immigration status, or showing that he had used falsified information or documents when applying for employment. Velasquez argued that evidence on such matters was inadmissible because (1) it was irrelevant as he was not claiming loss of earnings or earnings capacity; (2) it was more prejudicial than probative on any material issue, and thus excludable under Evidence Code section 352; and (3) it would constitute evidence of “bad acts” tending to prove character, and thus was inadmissible to challenge credibility under Evidence Code section 787.

In its opposition to Velasquez’s motion in limine No. 46, Advanced argued that evidence of Velasquez’s immigration status was admissible “for the limited purpose of allowing expert testimony ... on ... his ability to participate in a lung transplant,” which his complaint alleged he would need in the future. Advanced offered to stipulate to granting Velasquez’s motion in limine No. 46, provided he dropped his claim that he would need a lung transplant in the future.

In addition to the issues raised by motion in limine No.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Reyes-Gonzalez v. C & C North America CA2/7
California Court of Appeal, 2025
People v. Morales-Orellana CA5
California Court of Appeal, 2025
Riaz v. Altura Centers for Health CA5
California Court of Appeal, 2024
Temple of 1001 Buddhas v. City of Fremont
California Court of Appeal, 2024
Eagle Mist Corp. v. Laughlin CA2/3
California Court of Appeal, 2024
Robertson v. Robertson CA1/5
California Court of Appeal, 2023
FCM Investments v. Grove Pham, LLC
California Court of Appeal, 2023
People v. Zavala CA3
California Court of Appeal, 2023
Bader v. Johnson & Johnson
California Court of Appeal, 2022
Khoiny v. Dignity Health
California Court of Appeal, 2022
People v. Bayne CA4/1
California Court of Appeal, 2021
Tran v. 2000 Senter Road, LLC CA4/1
California Court of Appeal, 2021
People v. Casillas
California Court of Appeal, 2021
People v. Montoya CA6
California Court of Appeal, 2021
People v. Rios CA2/8
California Court of Appeal, 2021
People v. Johnson
California Court of Appeal, 2018
People v. Johnson
236 Cal. Rptr. 3d 13 (California Court of Appeals, 5th District, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
233 Cal. App. 4th 1191, 183 Cal. Rptr. 3d 150, 80 Cal. Comp. Cases 134, 2015 Cal. App. LEXIS 90, Counsel Stack Legal Research, https://law.counselstack.com/opinion/velasquez-v-centrome-inc-calctapp-2015.